NASDAQ:VXRT - Vaxart Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.93 0.00 (0.00 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$1.93
Today's Range$1.93 - $2.02
52-Week Range$1.65 - $8.05
Volume18,933 shs
Average Volume62,073 shs
Market Capitalization$13.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 million
Book Value$1.57 per share

Profitability

Net Income$-18,000,000.00
Net Margins-441.12%

Miscellaneous

Employees34
Market Cap$13.78 million
OptionableNot Optionable

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) released its earnings results on Friday, November, 9th. The biotechnology company reported ($0.92) earnings per share for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Vaxart had a negative return on equity of 82.05% and a negative net margin of 441.12%. View Vaxart's Earnings History.

When is Vaxart's next earnings date?

Vaxart is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Vaxart.

Has Vaxart been receiving favorable news coverage?

Headlines about VXRT stock have trended positive on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vaxart earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.

Who are some of Vaxart's key competitors?

Who are Vaxart's key executives?

Vaxart's management team includes the folowing people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO & Director (Age 62)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, CFO, Treasurer & Sec. (Age 67)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations
  • Dr. David N. Taylor, Chief Medical Officer (Age 70)

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.25%). View Institutional Ownership Trends for Vaxart.

Which institutional investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. View Insider Buying and Selling for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $1.93.

How big of a company is Vaxart?

Vaxart has a market capitalization of $13.78 million and generates $4.16 million in revenue each year. Vaxart employs 34 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is http://www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]


MarketBeat Community Rating for Vaxart (NASDAQ VXRT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel